NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Novavax, Inc.

20 Firstfield Road
Gaithersburg, MD 20878
United States

Full Time Employees346

Key Executives

Mr. Stanley Charles ErckChief Exec. Officer, Pres and Director625.38k1.56M69
Mr. Barclay A. PhillipsChief Financial Officer, Sr. VP and Treasurer370.75kN/A54
Mr. John Joseph Trizzino B.S., M.B.A.Sr. VP of Commercial Operations366.89kN/A57
Mr. John A. Herrmann III, J.D.Sr. VP, Gen. Counsel and Corp. Sec.342.5kN/A51
Dr. Gregory M. Glenn M.D.Pres of R&D448.75kN/A63
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

Novavax, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 6. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.